Introduction
============

Vascular endothelial growth factor (VEGF) is a critical regulator of angiogenesis in physiological and pathophysiological states. The VEGF family consists of number of secreted proteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor (PlGF), with VEGF-A being the most widely studied of the group. VEGF plays a crucial role in vasculogenesis and developmental angiogenesis ([@B73]; [@B12]) and adult vascular permeability and homeostasis ([@B52]; [@B53]; [@B20]). Dysregulation in VEGF signaling contributes to a wide array of diseases including cancer ([@B51]; [@B15]), wound healing ([@B6]), age-related macular degeneration ([@B27]), and peripheral arterial disease (PAD) ([@B56]; [@B1]; [@B10]; [@B16]; [@B17]). The response to VEGF is mediated by its binding to multiple receptors and co-receptors on endothelial cells such as VEGF receptor 2 (VEGFR2) and neuropilin-1 (NRP1). VEGF binding to receptor tyrosine kinase VEGFR2 leads to the activation of downstream signaling pathways including ERK1/2 and PI3K/Akt that induce cellular proliferation, survival, motility, and enhanced vascular permeability ([@B62]; [@B21]; [@B76]), the dominant pathway in post-natal angiogenesis. VEGF-VEGFR2 activation also induces nitric oxide (NO) release as a result of the activation of endothelial nitric oxide synthase (eNOS), substantially contributing to the angiogenic response ([@B63]; [@B30]).

Physiological VEGF signaling is tightly regulated by a balance of promoters and inhibitors of angiogenesis ([@B28]). Among the first identified endogenous inhibitors of angiogenesis was the matricellular protein thrombospondin-1 (TSP1) ([@B2]; [@B32]; [@B82]). TSP1 potently inhibits VEGF signaling at multiple levels. At nanomolar concentrations, TSP1 can directly bind and sequester VEGF ([@B35]) or lead to the internalization of TSP1--VEGF complex via binding to the TSP1 receptor LDL-related receptor protein 1 (LRP1) ([@B34]). At these concentrations, TSP1 may also inhibit Akt/eNOS/NO signaling by binding to the cell surface receptor CD36 ([@B41]). Binding of TSP1 to CD36, a fatty acid translocase, also inhibits its ability to uptake myristate into endothelial cells inhibiting activation of Src kinases and cGMP signaling ([@B41]). At picomolar concentrations, TSP1 potently inhibits angiogenesis by binding to CD47, an integrin associate glycoprotein membrane receptor ([@B48]). CD47 is the necessary TSP1 receptor for the inhibition of signals downstream of NO namely soluble guanylate cyclase (sGC) and cGMP-dependent protein kinase ([@B44], [@B45]). TSP1--CD47 interaction also inhibits eNOS activation and eNOS-dependent endothelial cell vasorelaxation ([@B7]). Adding to the empirical evidence is the result that mice deficient in CD47 or TSP1 show enhanced angiogenesis in models of wound healing ([@B43]).

TSP1--CD47 interaction has been demonstrated to potently inhibit VEGFR2 phosphorylation and Akt activation ([@B48]). Indeed, suppression of CD47 or downregulation of its expression rescued VEGFR2 phosphorylation indicating that the anti-angiogenic phenotype initiated by TSP1--CD47 interaction goes beyond mere inhibition of NO signaling pointing toward a role in a more global inhibitory effects ([@B48]).

Considering the complexity of receptor-level interactions and downstream signaling, computational models should prove expedient in elucidating and clarifying molecular mechanisms involved in TSP1--CD47 interaction with other receptors and suggest new avenues for experimental investigation. Moreover, computational models may inform and discriminate between various therapeutic modalities targeting TSP1--CD47 signaling.

Recently, computational modeling has been applied to investigate the mechanism of inhibition of VEGF signaling by TSP1--CD47 interaction and also test several therapeutic interventions ([@B8]). A detailed computational model of TSP1 was also developed within the context of cancer to investigate intervention mimicking the anti-angiogenic activity of TSP1 ([@B66]). In order to be relevant, the computational models require detailed signaling modules that include VEGF-VEGFR2 signaling to downstream pathways such as ERK1/2 and PI3K/Akt, which are subsequently integrated with TSP1--CD47 interaction. Detailed computational models of VEGF-VEGFR2 signaling incorporating detailed receptor dynamics have been developed in the past including signaling to ERK1/2 and calcium (Ca) ([@B81]; [@B85]; [@B18]; [@B9]), and PI3K/Akt ([@B80]).

Extending this to look at a different arm of VEGF signaling pathway and angiogenesis, our aim in this study is to build upon previous models of VEGFR2 signaling and present a fundamentally novel computational model of VEGF signaling to PI3K/Akt that takes into account recent experimental data in endothelial cells demonstrating the critical role of the receptor Axl-1 and Src in transducing VEGFR2 activation signal to PI3K/Akt ([@B67]). We also include a Ca--calmodulin (Ca/CaM) activation module to investigate the activation of eNOS by Ca/CaM and Akt phosphorylation. The inclusion of eNOS activation into our model downstream of VEGFR2 is motivated by experimental data demonstrating that eNOS-deficient mice have compromised angiogenesis in response to VEGF ([@B30]). The model is then utilized to investigate potential molecular mechanisms for the experimentally observed inhibition of signaling to Akt by TSP1 ([@B48]) and whether these mechanisms may also predict the inhibition of VEGF-induced eNOS activation ([@B26]; [@B14]). Experimentally, there is scant report in the literature suggesting a role for enhanced degradation of VEGFR2 by TSP1 that may contribute to the inhibitory action of TSP1 on VEGF signaling ([@B49]). A previous model confirmed that this is sufficient to explain the inhibition of VEGF signaling to ERK1/2 and Ca ([@B8]). Here, we utilize a more complex receptor cycling model to evaluate whether enhanced degradation hypothesis is sufficient to explain signal inhibition to both Akt and eNOS or whether other mechanisms should be considered.

Clinically, TSP1--CD47 signaling axis might offer an attractive target for pro-angiogenic interventions in diseases such as PAD ([@B77]) and impaired wound healing ([@B65]; [@B78]). Our computational model provides a platform to test whether targeting TSP1 or CD47 might be sufficient in rescuing VEGF signaling to Akt and eNOS; hence, paving the way for further validation of these targets for pro-angiogenic therapy.

Materials and Methods {#s1}
=====================

The rule-based programming language BioNetGen was used to generate reaction network based on the input biological rules ([@B37]; [@B25]). The final model consisted of 824 species (set of 824 ordinary differential equations) interacting via 5467 elementary biochemical reactions. The text of the BioNetGen file is provided as a supplement with the rules and initial seed species defined. The description of the species, rules, and coarse-grained model of signaling is also provided as a Supplementary File. It should be noted that BioNetGen is used for accurately capturing all the different receptor complexes in the model and for conveniently capturing all the reaction rules. Using BioNetGen also avoids manual formulation of the model that would require *a priori* knowledge of all the intermediate reaction steps. The model is simulated within MATLAB 2015b (MathWorks, Natick, MA, United States) using the Sundials solver suite ([@B36]). Optimization to determine parameter values was performed using the direct search algorithm, *patternsearch* as part of MATLAB global optimization toolbox. The set of rules for receptor interaction levels are contained in the text file and the model is also presented in Systems Biology Markup Language (SBML) format. Western blot data from the literature were quantified using ImageJ ([@B72]).

Results
=======

Model Construction: Receptor-Level Interactions and Downstream Signaling
------------------------------------------------------------------------

Detailed receptor interaction module was constructed using a rule-based methodology utilizing BioNetGen similar to previous studies ([@B37]; [@B66]; [@B8]; [@B9]). As shown in **Figure [1A](#F1){ref-type="fig"}**, the seed species include the ligand VEGF-A with two binding sites (r) for the receptor and a single binding site for the coreceptor NRP1 (NRP1bd). VEGFR2 has a ligand-binding site (L), a tyrosine phosphorylation site (represented as Y1175), and a ligand independent coupling site (c).

![Receptor level rules, species, and dynamics. **(A)** Seed species in the model include the ligand VEGF, VEGFR2, VEGFR1, NRP1, CD47, and TSP1 with binding domains and modification sites indicated in the figure. **(B)** Rules for VEGF-dependent receptor dimerization, VEGF binding to NRP1, and TSP1 binding to CD47 are illustrated. **(C)** Rules for VEGFR1 binding with NRP1, VEGF-mediated VEGFR1 (R1)/VEGFR2 (R2) heterodimerization are shown. **(D)** The rule for the constitutive binding of VEGFR2 to CD47. **(E)** Ligand-independent receptor coupling and receptor autophosphorylation rules. **(F)** Receptor internalization when VEGFR2 is homodimerized by VEGF. The model includes two compartments as signaling endosomes. Transport from signaling endosomes to recycling endosomes occurs when NRP1 is part of the receptor complex. TSP1 may modify the transport of vesicles to the recycling endosome or enhance the degradation of VEGFR2 from the early endosomes. Ligands are dissociated from receptors in recycling endosomes. Only non-phosphorylated receptors recycle back to the membrane from the recycling endosomes.](fphys-09-00644-g001){#F1}

In effect, we lump together different phosphorylation sites on VEGFR2 to simplify the model. Signaling from distinct phosphorylation site may be incorporated into the BioNetGen description as more experimental data become available. VEGFR1 contains a single binding site for the ligand (L) and another for NRP1 (NRP1bd), and a ligand-independent coupling domain (c). NRP1 has a single-binding site for both the ligand and VEGFR1 (R1bd/L) ([@B29]). The main receptor for TSP1 is assumed to be CD47 that has a binding site for VEGFR2 and another for TSP1. The rules for VEGF-dependent receptor dimerization are summarized in **Figure [1B](#F1){ref-type="fig"}**. TSP1 binds to VEGFR2-coupled CD47 (**Figure [1C](#F1){ref-type="fig"}**). Biologically, TSP1 is a tetramer with potentially three different binding sites for CD47, but to simplify the model, we assume that TSP1 binding to CD47 is effectively a one-to-one interaction. VEGFR1 and NRP1 interact constitutively as shown in **Figure [1D](#F1){ref-type="fig"}**. VEGFR1/VEGFR2 heterodimerization is also included along with constitutive binding of VEGFR2 to CD47 (**Figure [1D](#F1){ref-type="fig"}**). For completeness, model here includes ligand-independent dimerization as shown in **Figure [1E](#F1){ref-type="fig"}** ([@B61]; [@B55]). Engagement of VEGF with two VEGFR2 receptors leads to autophosphorylation of the receptors (**Figure [1E](#F1){ref-type="fig"}**). Furthermore, VEGFR2 receptors internalize after the homodimerization induced by the binding of VEGF (**Figure [1F](#F1){ref-type="fig"}**). The model includes a multi-compartmental receptor cycling model that comprises two compartments as signaling endosomes to more accurately fit the experimental data (**Figure [1F](#F1){ref-type="fig"}**). The transition from the signaling endosome to the recycling endosome is dependent on NRP1 consistent with experimental data ([@B4]) and may be modified by TSP1. TSP1 may also affect the degradation of receptors from the signaling endosome as shown in the diagram (**Figure [1F](#F1){ref-type="fig"}**). Consistent with the experimental evidence, only unphosphorylated receptors cycle back to the plasma membrane from the recycling compartment ([@B4]). The signaling pathway downstream of the activated VEGFR2 is presented in **Figure [2A](#F2){ref-type="fig"}**.

![Signaling pathway to Akt, eNOS, and Ca/CaM downstream of VEGFR2. **(A)** Phosphorylated VEGFR2 (pR2) activates pSrc that transduces the signal to PI3K/AKT via Axl-1. Activation of pR2 leads to PLCγ activation that eventually results in Ca elevation and Ca/CaM activation. Ca/CaM is necessary for eNOS dissociation from caveolin-1 and initial activation. Activated Akt phosphorylated eNOS and fully activates it. **(B)** Ca cycling modules that include plasma membrane and SERCA Ca pumps, IP3-sensitive Ca release channels, and CRAC channels.](fphys-09-00644-g002){#F2}

The signal transduction pathway is constructed by taking into account recent experimental evidence demonstrating that Axl-1 and Src are crucial for the transduction of the signal from phosphorylated receptor to Akt ([@B67]; [@B79]). We also reviewed the information available on PI3K/AKT pathway in the Reactome Pathway Database in order to ensure the consistency of the pathway structure with the available data ([@B59]; [@B19]). TSAd and Src are lumped together (TSAd/Src) and activated (Src phosphorylation) as a function of phosphorylated VEGFR2 (pR2) presented in detailed in the Supplementary Materials ([@B79]; [@B33]). Activated Src phosphorylates Axl-1 which then induces Axl-1 autophosphorylation on a different site consistent with experimental data ([@B67],[@B68]). PI3K is then recruited and activated by Axl-1. Once in the membrane, PI3K phosphorylates PIP2 to generate PIP3. PIP3 recruits PDK1 and Akt to the membrane from the cytoplasm through their PH domains. The kinase mTOR phosphorylates Akt on serine 473 residue (S473) ([@B69]) followed by the phosphorylation of the threonine 308 residue (T308) residue on Akt by PDK1 ([@B70]).

A different arm of the pathway from the phosphorylated VEGFR2 is the activation of PLCγ ([@B58]) which leads to the elevation of IP3 and Ca release from the ER via the IP3-sensitive receptors (**Figure [2B](#F2){ref-type="fig"}**). Ca activates CaM which then binds eNOS--caveolin-1 complex and results in the dissociation of caveolin-1 and partial activation of eNOS ([@B23]; [@B3]). Phosphorylation of eNOS on serine 1177 residue (S1177) by activated Akt is included as shown in **Figure [2A](#F2){ref-type="fig"}**. Phosphorylated eNOS is fully active and is shown to be insensitive to Ca ([@B22]). The Ca module is similar to the previous model with Ca-induced Ca release channels (CRAC), ER release via IP3 receptors, and Ca pumps ([@B75]; [@B71]; [@B9]).

Model Parameterization and Sensitivity Analysis
-----------------------------------------------

To estimate model parameters, we fit the model to a consistent set of experimental data from human endothelial cells (HUVEC) as shown in **Figure [3](#F3){ref-type="fig"}**. **Figures [3A,B](#F3){ref-type="fig"}** show the model fit to the data for the normalized total receptor dynamics ([@B11]; [@B4]) and surface receptor level time course ([@B24]; [@B11]). The initial receptor levels were selected based on the measured experimental data in [@B38], [@B39]). In the absence of NRP1, VEGFR2 degradation is enhanced and there is little transfer of the internalized receptors to the recycling endosome ([@B4]).

![Fitting the model to experimental data. **(A)** Total receptor level versus time fitted to the data in [@B11] (red) and [@B4] (black). **(B)** Surface receptor versus time fitted to the data in [@B24] (red) and [@B11] (black). **(C)** Total receptor level in the presence (blue trace) and absence of NRP1 (red trace) fitted to the data in [@B4] (black). **(D)** Total receptor level under control condition. **(E)** Total receptor level in the presence of CHX and the absence of VEGF. **(F)** With VEGF and CHX. **(G)** Dynamics of pR2 traces versus time fitted to the data in [@B11] (red). **(H)** pR2 signaling from endosomal and membrane compartments. **(I)** PLCγ temporal dynamics fitted to the data in [@B13] (red). **(J)** Cytoplasmic Ca concentration fitted to the data in [@B54] (red). **(K)** Phosphorylated Src dynamics from the model fitted to the data in [@B67] (red). **(L)** Dynamics of Src-phosphorylated Axl-1 fitted to the data in [@B67] (red). **(M)** Dynamics of phosphorylated S473 on Akt fitted to the data in [@B67] (red). **(N)** Dynamics of phosphorylated T308 on Akt fitted to data in [@B67] (red). **(O)** Dynamics of phosphorylated S1177 on eNOS fitted to the data in [@B13] (red).](fphys-09-00644-g003){#F3}

The model correctly captures this as shown in **Figure [3C](#F3){ref-type="fig"}** (control trace with NRP1 is presented in blue versus simulation in red and experimental data shown as black circles). The model is also fitted to the data in the presence or absence of cycloheximide (CHX), a potent inhibitor of protein synthesis. This is to estimate the effective rate of protein synthesis in the model, namely the parameter ksingleR2~syn~. The model adequately fits the data under control condition (no VEGF, no CHX) as in **Figure [3D](#F3){ref-type="fig"}**. In the absence of CHX, the VEGFR2 levels drop considerably due to inhibition of receptor synthesis (**Figure [3E](#F3){ref-type="fig"}** versus **Figure [3D](#F3){ref-type="fig"}**). With both VEGF and CHX present, the drop in VEGFR2 levels is even faster, fitting the available experimental data (**Figure [3F](#F3){ref-type="fig"}**).

While constructing the model we determined that having two signaling internalized compartments (**Figure [1F](#F1){ref-type="fig"}**) was necessary for better fitting of the model to the set of data on receptor dynamics. The value of ksingleR2~syn~ is computed to be about 1.4e-4 s^-1^ (this translates into a synthesis rate of ∼0.84 receptor/s). The normalized phosphorylated VEGFR2 versus time is fitted to the data in [@B13] and shows the expected rapid transient increase in phosphorylated VEGFR2 that decreases to lower levels at the steady state (**Figure [3G](#F3){ref-type="fig"}**).

It is important to differentiate how much of the downstream signal comes from activated VEGFR2 on the membrane versus endosomes (**Figure [3H](#F3){ref-type="fig"}**). The model predicts that the majority of the signal comes from the internalized receptors (red line) while the signal from surface receptors is short lived (blue). Note that this is an emergent property of the model and is not an *a priori* assumption. In fact, this is consistent with recent experimental evidence demonstrating that in many receptor tyrosine kinases including VEGFR2 the bulk of signaling comes from the internalized receptors ([@B83]).

To fit the Ca regulation arm of the pathway, phosphorylated PLCγ trace from the model is fitted to the experimental data in [@B13]; **Figure [3I](#F3){ref-type="fig"}**). Additionally, the cytoplasmic Ca trace from the model and the data from [@B54] are fitted (**Figure [3J](#F3){ref-type="fig"}**) to constrain the parameters for the Ca cycling module. For the signaling to PI3K/AKT the data in [@B67] were utilized. Phosphorylated Src and the corresponding data points are shown in **Figure [3K](#F3){ref-type="fig"}**. Also shown in **Figure [3L](#F3){ref-type="fig"}**, is the Src phosphorylated Axl-1 dynamics fitted to the data points. The traces for the phosphorylation of S473 and T308 residues on Akt are shown in **Figures [3M,N](#F3){ref-type="fig"}**, respectively; the data points are taken from [@B13]. The Akt-phosphorylated eNOS (on S1177) trace is shown in **Figure [3O](#F3){ref-type="fig"}** along with the experimental data from [@B13]. Rich set of experimental data enabled us to achieve a good fit for the baseline model allowing further investigation of the therapeutic interventions on important pathway outputs (i.e., Akt and eNOS). The parameter values along with descriptions are given in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

Global sensitivity analysis is then carried out using the partial rank correlation coefficient (PRCC) method described in [@B57] to identify the most sensitive parameters that determine the activation of Akt and eNOS. The results are summarized in **Figure [4](#F4){ref-type="fig"}**. Both positively and negatively correlated parameters are included. The sensitive positively and negatively correlated parameters determining the activation of S473 on Akt are shown in **Figures [4A,B](#F4){ref-type="fig"}**. The top positively correlated parameters (**Figure [4A](#F4){ref-type="fig"}**) are the catalytic rate of PI3K (kcat~PI3KPIP2~), PIP3 concentration for half activation of PTEN (km~PIP3PTEN~), the total level of PI3K (PI3K~0~), and several parameters determining activation of Axl-1 (kon~PI3KAxl~, Axl~0~, kp~Axlauto~, kp~SrcAxl~). Notably, synthesis rate of VEGFR2 (ksingleR2~syn~) and the on-rate for the binding of VEGF to NRP1 (kVEGFNRP1~on~) are also significant parameters. The top negatively correlated parameters include the total level of PTEN (PTEN~0~), the catalytic rate of PTEN (kcat~PTENPIP3~), the PIP3 concentration for half-maximal activation of PI3K (km~PIP2PI3K~), the inactivation rate of PI3K (koff~PI3KAxl~), and the dephosphorylation rate of Axl-1 (kdp~autoAxl~ and kdp~SrcAxl~). Other notable parameters include the catalytic rate of PLCγ (kcat~PLCγDAG~), the off-rate of VEGF-VEGFR2 unbinding from NRP1 (kVEGFR2NRP1~off~), and the internalization rate of VEGFR2 in the absence of NRP1 (kr2~si~).

![Global sensitivity analysis using PRCC. **(A)** Ranking of positively correlated parameters determining pS473 on Akt. **(B)** Ranking of negatively correlated parameters determining pS473. **(C)** Positively correlated parameters ranked in the order of sensitivity determining doubly phosphorylated Akt. **(D)** Negatively correlated parameters ranked in the order of sensitivity determining doubly phosphorylated Akt. **(E)** Ranking of positively correlated parameters determining pS1177. **(F)** Ranking of negatively correlated parameters.](fphys-09-00644-g004){#F4}

For the doubly phosphorylated Akt (phosphorylated on both S473 and T308), the top positively correlated parameters are the total level of PI3K, the autophosphorylation rate of Axl-1 (kp~Axlauto~), and the rate of PI3K activation by Axl-1 (kon~PI3KAxl~). The total level of Axl-1 (Axl~0~) and Src (Src~0~) and the phosphorylation rate of VEGFR2 are significant. Other notable parameters are VEGFR2 synthesis rate, the on-rate of VEGF binding to NRP1 (kVEGFNRP1~on~), and ligand-independent decoupling rate between receptors (kd~RR~).

The top negatively correlated parameters are the dephosphorylation rate of autophosphorylated Axl-1, the rate of PI3K inactivation, and the dephosphorylation rate of the site on Axl-1 phosphorylated by Src. Other notable parameters include the dephosphorylation rate of VEGFR2 (kdp~s~ and kdp~i~), and the degradation rate of the receptor (kdeg~i0noP~ and kdeg~i0~). The top positively correlated parameters determining phosphorylated eNOS on S1177 are the amplitude of the CRAC channel current (ICRAC~amp~), the total level of PIP2 (PIP2~0~), the on-rate of Ca/CaM binding to eNOS--caveolin complex, and the amplitude of current through the IP3-sensitive receptors (Iip3R~amp~). The synthesis rate of VEGFR2 and catalytic rate of PLCγ are also notable positively correlated parameters. Top negatively correlated parameters are the current through the SERCA pump (v~SERCA~), the degradation rate of IP3 (kdeg~ip3~), and the plasma membrane Ca pump rate (IPMCA~amp~).

Sensitivity analysis provides general understanding of the mechanisms that determine the activation of Akt and eNOS and specifies the rate limiting factors within the context of this model in the presence of VEGF. We next apply the model to test potential mechanisms for the inhibition of signaling to Akt and eNOS by TSP1.

Enhanced Degradation of VEGFR2 From the Signaling Endosomes by TSP1 Is Sufficient to Explain the Inhibition of eNOS Activation by TSP1
--------------------------------------------------------------------------------------------------------------------------------------

There is experimental evidence that TSP1 binding to CD47 inhibits VEGFR2, Akt, and Src activation ([@B48], [@B47]). There is also limited experimental evidence that TSP1 accelerates the degradation of VEGFR2 ([@B49]). In a previous modeling investigation, this enhanced degradation by TSP1 was sufficient to explain the inhibition of VEGFR2 activation and downstream signaling ([@B8]). In this study, we aimed at utilizing our detailed multi-compartmental model of receptor cycling to distinguish between two competing mechanisms for enhancing the degradation of VEGFR2 by TSP1. For the simulations in this section, 2.2 nM TSP1 is added for 10 min before addition 50 ng/ml VEGF similar to the experimental protocol ([@B48]).

The first possibility is that TSP1 inhibits the transport of receptors from the signaling endosomes to the recycling endosome as illustrated in **Figure [5A](#F5){ref-type="fig"}**. The effect is modeled by the parameter fTSP1~i2r~ which takes values between 0 (total inhibition of transport) and 1 (control). As demonstrated by the simulations in **Figures [5B](#F5){ref-type="fig"}--[D](#F5){ref-type="fig"}**, total block of receptor transport from signaling endosomes to the recycling endosomes only slightly reduces VEGFR2 phosphorylation (**Figure [5B](#F5){ref-type="fig"}**), Akt activation (**Figure [5C](#F5){ref-type="fig"}**), or eNOS phosphorylation (**Figure [5D](#F5){ref-type="fig"}**).

![Mechanisms for the inhibition of VEGFR2 signaling to Akt and eNOS by TSP1. **(A)** Potential mechanism for TSP1 inhibition of VEGFR2 activation involving the blockade of receptor trafficking from signaling endosomes to recycling endosomes. **(B)** pR2 temporal dynamics under control (red) and complete trafficking inhibition conditions (blue). **(C)** Akt dynamics of pS473. **(D)** Dynamics of eNOS phosphorylation on S1177. **(E)** Mechanisms of TSP1 inhibition involving enhanced degradation of VEGFR2 from the signaling endosomes. **(F)** Traces of pR2 in response to changes in TSP1-mediated degradation parameter. **(G)** Maximum pR2 versus the degradation parameter. **(H)** Traces illustrating the dynamics of pS473 on Akt in response to changes in enhanced degradation parameter. **(I)** Maximum pS473 on Akt versus enhanced degradation parameter. **(J)** Dynamics of pS1177 on eNOS as a response to changes in receptor degradation. **(K)** Maximum pS1177 on eNOS as a function of enhanced degradation of receptors indicating sensitive dependence on TSP1-mediated enhancement of degradation. **(L)** Maximum peNOS versus maximum Ca/CaM illustrating a near-perfect linear relation.](fphys-09-00644-g005){#F5}

The second mechanism for TSP1 inhibition of VEGFR2 signaling considered here is that TSP1 enhances degradation from the signaling endosomes (**Figure [5E](#F5){ref-type="fig"}**, also see **Figure [1F](#F1){ref-type="fig"}**). This is modeled by the parameter fTSP1~deg~ (equals 1 for control, \>1 when simulating enhanced degradation). As shown in **Figure [5F](#F5){ref-type="fig"}**, this mechanism is sufficient to explain inhibition of VEGFR2 phosphorylation as a fivefold increase in degradation represses pR2. **Figure [5G](#F5){ref-type="fig"}** illustrates the changes in maximum pR2 as a function of enhanced degradation. Increasing degradation ∼20-fold is predicted to be sufficient to lead to near maximal inhibition. The degradation from signaling endosomes also reduces Akt activation as shown in **Figure [5H](#F5){ref-type="fig"}**, however, the inhibition plateaus (**Figure [5I](#F5){ref-type="fig"}**).

Current mechanism, therefore, does not explain full inhibition of Akt phosphorylation on S473 observed experimentally ([@B48]). This suggests that there is sufficient signaling from the surface receptors to activate Akt on S473. This implies that there are other mechanisms at play that contribute to full inhibition of Akt activation.

However, activation of eNOS is potently inhibited by the proposed mechanism as shown in **Figures [5J,K](#F5){ref-type="fig"}**. A fourfold increase in degradation is sufficient to abolish eNOS activation (**Figure [5J](#F5){ref-type="fig"}**). Interestingly, max peNOS is linearly correlated with max CaCaM (**Figure [5L](#F5){ref-type="fig"}**) predicting that the inhibition is mainly through the inhibition of Ca/CaM. In other words, TSP1 effect on VEGFR2 potently inhibits Ca/CaM elevation downstream of VEGFR2 thereby blocking the initial activation of eNOS by Ca/CaM, the necessary step in the activation of eNOS ([@B23]; [@B3]).

Phosphatase Recruitment to VEGFR2 Is Necessary to Explain the Complete Inhibition of Akt Phosphorylation on S473 by TSP1
------------------------------------------------------------------------------------------------------------------------

Simulations in the previous section indicated that enhanced degradation of receptors by TSP1 from signaling endosomes was not sufficient in itself to explain Akt inhibition of phosphorylation on S473. We thus postulated that phosphatase recruitment to the receptor by TSP1--CD47 interaction might explain full inhibition of Akt and in concert with enhanced degradation mechanism explain the full range of TSP1 inhibitory effects. Phosphatase recruitment to CD47 by TSP1 has been observed experimentally and might support the proposal here ([@B84]).

The simulations should be viewed as test of hypothesis that should motivate and guide additional experimental investigation. The proposed mechanism is illustrated in **Figure [6A](#F6){ref-type="fig"}** and modeled by parameter fTSP1~dp~ which describes potential increase in phosphatase recruitment to surface receptors (control value of 1). Traces in **Figure [6B](#F6){ref-type="fig"}** demonstrate the effectiveness of this mechanism in inhibiting Akt activation. **Figure [6C](#F6){ref-type="fig"}** further shows that 20-fold increase in dephosphorylation rate potently inhibits Akt activation. In reality, it is plausible for both enhanced degradation and phosphatase recruitment mechanisms to work in concert as shown in **Figure [6D](#F6){ref-type="fig"}** that shows the effect of changing both parameters on Akt activation. What the simulation shows is that a 10-fold increase in dephosphorylation and degradation each would be sufficient to explain TSP1 inhibition. Phosphatase recruitment would also augment enhanced degradation in the inhibition of eNOS activation as shown in **Figures [6E,F](#F6){ref-type="fig"}**. What these simulations show is that when both mechanisms work in concert, the inhibitory effect of TSP1 may be very potent.

![Phosphatase recruitment by TSP1 is required for complete inhibition of Akt phosphorylation on S473. **(A)** Diagram illustrating phosphatase recruitment to the receptor by TSP1-CD47. **(B)** Akt activation is efficiently inhibited by changes in membrane dephosphorylation rate mediated by TSP1. **(C)** Maximum Akt phosphorylation on S473 versus phosphatase recruitment parameter. **(D)** Two-parameter scan for maximum pS473 when both enhanced degradation and phosphatase recruitment are involved. **(E)** Sensitive dependence of eNOS phosphorylation to increases in membrane level dephosphorylation by TSP1. **(F)** Two-parameter scan for pS1177 on eNOS in response to TSP1-mediated changes in enhanced degradation and phosphatase recruitment.](fphys-09-00644-g006){#F6}

In the next section, we utilize this knowledge to perform simulations for the inhibition of TSP1--CD47 signaling as pro-angiogenic intervention.

Inhibition of TSP1--CD47 Axis to Rescue VEGF Signaling
------------------------------------------------------

Previous simulations illustrate that TSP1--CD47 inhibition is very effective in shutting down VEGF signaling to Akt and eNOS via enhancing the degradation of VEGFR2 from signaling endosome coupled with phosphatase recruitment to the plasma membrane. Simulations indicated that a 10-fold increase in both phosphatase recruitment and VEGFR2 degradation would effectively block both Akt and eNOS activation. Here we aim at utilizing the model to test different interventions to best rescue VEGF signaling to Akt and eNOS in the presence of TSP1. This may be relevant to disease conditions such as wound healing and PAD where angiogenesis mediated by VEGF may be compromised. We initially simulate the effect of depleting TSP1 in the extracellular space; for example, under *in vivo* conditions such depletion could be achieved by administration of a TSP1-specific antibody. As shown in **Figures [7A,B](#F7){ref-type="fig"}**, 80% depletion of TSP1 is necessary for the Akt activation signal to begin to recover (**Figure [7A](#F7){ref-type="fig"}**) and for effective rescue of Akt signal, a 98% inhibition is necessary (**Figure [7B](#F7){ref-type="fig"}**). However, this is unlikely to be achievable physiologically. The rescue of eNOS activation with this intervention is even less efficient as shown in **Figures [7C,D](#F7){ref-type="fig"}**. We next postulate that depleting CD47, the receptor for TSP1, might be more efficient in the restoration of VEGF signaling to Akt and eNOS. Indeed, Akt activation is restored in a linear fashion after ∼30% of CD47 were depleted (**Figure [7E](#F7){ref-type="fig"}**). The reason for the initial delay is that assumed total CD47 level of 10,000 receptors is higher than the total number of VEGFR2 at 6000. Because VEGFR2 and CD47 are constitutively associated with each other, initial depletion is necessary to reduce the number of CD47 to a comparable level as VEGFR2. The traces in **Figure [7F](#F7){ref-type="fig"}** show the gradual restoration in Akt activation.

![Rescuing VEGF signaling to Akt and eNOS by targeting TSP1 or CD47. **(A)** Depletion of TSP1 and the predicted recovery of pS473 on Akt. **(B)** Sample traces for pS473 for different values of TSP1 inhibition. **(C)** Recovery of max pS1177 on eNOS in response to TSP1 inhibition. **(D)** Sample traces for phosphorylated eNOS. **(E)** Rescue of Akt phosphorylation on S473 with depletion of CD47 indicating a linear recovery. **(F)** Sample traces for pS473 for different depletion levels. **(G)** pS1177 in response to CD47 depletion. **(H)** Sample pS1177 traces requiring over 90% depletion for sufficient recovery of the activation signal. **(I)** Combining CD47 depletion with the inhibition of TSP1 binding to CD47 achieved by increasing the Kd of TSP1-CD47 binding. Akt activation recovery for different values of increased Kd relative to control (blue, the lowest curve). **(J)** Restoring Akt signaling when 50% CD47 depletion is combined with TSP1-CD47 binding inhibition. **(K)** Improved recovery of maximum pS1177 on eNOS under combination intervention. **(L)** The temporal recovery traces for pS1177 when 50% depletion in CD47 is combined with inhibition of TSP1 binding to CD47 as shown by the increase in Kd.](fphys-09-00644-g007){#F7}

While eNOS activation in response to CD47 inhibition is less steep than the case of TSP1 depletion (**Figure [7G](#F7){ref-type="fig"}** versus **Figure [7C](#F7){ref-type="fig"}**), the simulations still predict difficulty in the plausibility of targeting CD47 to rescue eNOS. The recovery curve still has a strong switching behavior with minimum 80% depletion necessary for peNOS recovery. The traces for peNOS in **Figure [7H](#F7){ref-type="fig"}** also indicate that 96% inhibition may be required to sufficiently restore eNOS activation.

The model predicts that neither CD47 nor TSP1 depletion is efficient in eNOS activation rescue. We therefore hypothesized that combining CD47 depletion with a hypothetical therapy that inhibits TSP1 binding to CD47 (modeled by increasing the Kd of TSP1 binding to CD47) may produce a better recovery curve for both Akt and eNOS. Indeed, simulations predict that a hypothetical therapy, such as a TSP1-specific antibody, that sequesters TSP1 and reduces TSP1 binding to CD47 by 10-fold (increasing Kd by 10-fold), improves the anti-CD47 recovery curve for Akt (**Figure [7I](#F7){ref-type="fig"}**, the blue trace for control Kd versus the purple trace with 10× Kd). Considering a different scenario, suppose CD47 is depleted by 50%, then a 23-fold reduction in TSP1 binding to CD47 would result in near complete recovery of Akt (**Figure [7J](#F7){ref-type="fig"}**, black trace). Similarly, the recovery in maximum eNOS is much improved if both interventions are combined as in **Figure [7K](#F7){ref-type="fig"}**. As illustrated in **Figure [7K](#F7){ref-type="fig"}**, a 70-fold decrease in the binding of TSP1 to CD47 (a 70-fold increase in Kd) by a hypothetical compound would significantly improve the recovery of eNOS activation in response to CD47 depletion (**Figure [7K](#F7){ref-type="fig"}**, blue trace).

Suppose again that 50% of CD47 has been depleted, a 52-fold reduction in the binding of TSP1 to CD47 would lead to a significant restoration of eNOS activation signal (**Figure [7L](#F7){ref-type="fig"}**, purple curve). Simulations here predict that while Akt activation may be rescued efficiently by targeting CD47 alone (rather than TSP1), to effectively restore eNOS activation, combination therapies that target both CD47 and another mechanism such as the binding of TSP1 to CD47 may be necessary. Overall, computational modeling suggests that targeting TSP1--CD47 axis has potential as a pro-angiogenic intervention. Modeling results also suggest that inhibiting CD47 might be more advantageous than TSP1 alone. However, a dual approach that captures both TSP1 and CD47 is predicted to be optimal.

Discussion
==========

A detailed model of VEGFR2 signaling to Akt and eNOS was constructed in order to test precise mechanisms of the experimentally observed inhibition of this pathway by TSP1 ([@B48], [@B47]). Empirically, TSP1 has been found to affect VEGFR2 trafficking and degradation ([@B49]). Considering the available evidence, we tested two different nodes that might be targets for TSP1 effects. TSP1 may inhibit VEGFR2 transport from signaling endosomes to recycling endosomes, hence, preventing the recycling of the receptors to the membrane. Interestingly, the model predicted that this mechanism did not lead to the inhibition of VEGFR2 phosphorylation, Akt activation, and eNOS phosphorylation on S1177. This is consistent with experimental data showing that siRNA knockdown of NRP1 does not abolish VEGFR2 activation, and that cell migration is compromised via the inhibition of focal adhesion kinases. The model, however, showed that enhancing receptor degradation from early endosomes can explain the inhibition of VEGFR2 and eNOS activation, and partially the inhibition of Akt phosphorylation on S473. This implied that signaling from membrane-bound receptors is sufficient to sustain Akt signaling. We thus hypothesized that phosphatase recruitment by TSP1--CD47 may explain the complete inhibition of Akt phosphorylation on S473 observed experimentally. The phosphatase recruitment hypothesis was indeed predicted to be very effective in shutting down Akt activation.

An interesting outcome of the simulations presented here is that TSP1 is particularly effective in inhibition of eNOS and that eNOS activation is very sensitive to perturbations introduced by TSP1--CD47. This may provide a mechanistic explanation for potent inhibition of NO signaling by TSP1. Simulations further suggest that the main mechanism for the sensitive inhibition of eNOS activation is through inhibition of Ca/CaM. The effect on Ca/CaM signaling by TSP1 has not been explored in detail within current experimental literature. Our computational model suggests the need for further investigations in this area as we predict a potent inhibition of Ca/CaM signaling by TSP1 that may go beyond eNOS and influence other Ca/CaM targets in endothelial as well as other cell types. As Ca/CaM signaling plays critical roles in VEGF-induced angiogenesis ([@B74]; [@B46]; [@B5]), its potent inhibition by TSP1--CD47 may be another hallmark of TSP1 signaling.

Given the versatility of TSP1--CD47 interaction in blocking angiogenesis, it is plausible to explore the possibility of inhibiting TSP1, CD47, or both together as strategies to enhance or rescue angiogenesis. Blocking TSP1 and CD47 has already been explored in different setting. For example, inhibiting CD47 alleviates pathogenic effects of aging, a process that may be associated with deterioration in angiogenic capacity, on different tissues in response to ischemia ([@B40], [@B42],[@B43]). Utilizing our model, we simulated different strategies for the inhibition of TSP1--CD47 signaling to evaluate the recovery response of Akt and eNOS. Our simulations predict that depleting CD47 is more advantageous in rescuing Akt signal in response to VEGF; however, with regards to eNOS activation, our model predicts that combination therapy combining CD47 depletion with the inhibition of TSP1 binding to CD47 (hypothetical compound that effectively increases the dissociation constant) may be necessary for effective rescue. Given the highly non-linear nature of these signaling pathways, these non-trivial findings would have been difficult to hypothesize without the application of mechanistic modeling.

Model Limitations
-----------------

Thrombospondin-1 engages other receptors that could play a role in angiogenesis and these should be tested in future studies. Another limiting factor in all these predictions is that the model only considers VEGF signaling through VEGFR2 to Akt and eNOS and ignores other sources of eNOS activation in tissues. Moreover, the model ignores the pro-apoptotic signaling downstream of TSP1--CD47 that might override other angio-inhibitory signaling ([@B64]; [@B50]; [@B31]).

Thrombospondin-1 via CD47 can also adversely impact cellular metabolism under some conditions ([@B60]). Thus, the pro-survival action of TSP1--CD47 inhibition might be a more significant outcome than rescuing signals through VEGF. The computational model may be enhanced by incorporating mechanisms that control TSP1 expression \[such as miroRNAs as modeled in [@B86]\] which would enable investigation of different targeting strategies in combination with what we have already included here. However, in the absence of more clarifying data, our proof-of-concept simulations point at clear distinctions between multiple strategies for rescuing VEGF signaling by blocking TSP1--CD47 axis.

To summarize, the computational investigation here synthesizes available knowledge about VEGF signaling and TSP1--CD47 to propose molecular mechanisms of the inhibition of the VEGF pathway by TSP1. The mechanistic model also paves the way for *in silico* investigation of therapeutic strategies for promoting angiogenesis that may prove relevant for diseases such as PAD and other age-related conditions with no currently available effective therapies.
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